Assessment of CDKN2A homozygous and heterozygous deletions in gliomas across multiple detection platforms
Abstract Accurately identification of cyclin-dependent kinase inhibitor 2A (CDKN2A) status is of paramount important, as it has been reported as an unfavorable prognostic biomarker in diffuse gliomas, both IDH-mutant and IDH-wild type. Various methods are available for identifying CDKN2A deletion, w...
Saved in:
| Main Authors: | Hainan Li, Ningning Luo, Chongzhu Fan, Tiantian Han, Xuemin Wei, Xing Zhang, Lijun Dai, Lei Ye, Dongsheng Chen, Linbo Cai, Zhi Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14266-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
<i>CDKN2A</i> Homozygous Deletion Is a Stronger Predictor of Outcome than <i>IDH1/2</i>-Mutation in CNS WHO Grade 4 Gliomas
by: Sang Hyuk Lee, et al.
Published: (2024-10-01) -
Challenging CDKN2A assessment in BRAF-altered gliomas: lessons from a pleomorphic xanthoastrocytoma-enriched cohort
by: Thibaut Wolf, et al.
Published: (2025-08-01) -
Prevalence and prognostic impact of BRAF V600E mutation and CDKN2A deletion in pediatric high-grade glioma
by: Soha Karim, et al.
Published: (2025-08-01) -
Homozygous CDKN2A/B deletions in low- and high-grade glioma: a meta-analysis of individual patient data and predictive values of p16 immunohistochemistry testing
by: Darius Noack, et al.
Published: (2024-11-01) -
Association of CDKN2A/B deletions with survival of patients with diffuse large B-cell lymphoma
by: M. V. Sarpova, et al.
Published: (2024-01-01)